Semaglutide has shown superior weight loss outcomes compared to other medications and diet-based approaches, providing a more effective and long-lasting solution
Cardiovascular exercise Walking is massively underrated
Genetic variation in selenoprotein S influences inflammatory response
Learn to screen for contraindications (history of medullary thyroid cancer, multiple endocrine neoplasia, severe gastroparesis, etc.)
For individuals with diabetes and overweight or obesity, the ADA recommends as preferred pharmacotherapy a GLP-1 receptor agonist or a dual GLP-1/GIP receptor agonist with substantial weight-loss efficacy, meaning semaglutide or tirzepatide
This follow-up allows our providers to fine-tune dosing strategies, provide encouragement, and answer questions